The startup develops immunotherapy technologies that utilize tumor-specific antigens derived from endogenous retroviral DNA sequences to enhance cancer treatment efficacy. This approach enables hospitals to accurately assess tumor specificity and immunogenic potential, improving cancer monitoring and management.
Funding
$82.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MVPVFounders
Product
Problem
Current cancer immunotherapies often fail to provide lasting benefits for a broad range of patients with solid tumors due to a lack of cancer-specific targets. Conventional tumor-associated antigens are often seen as "self" by the immune system, limiting their immunogenicity and therapeutic potential.
Solution
Enara Bio is developing cancer immunotherapies by targeting Dark Antigens, a novel class of cancer-specific targets derived from previously uncharted genomic dark matter. The company's EDAPT platform integrates bioinformatics, immunopeptidomics, and tumor biology to discover and validate these Dark Antigens, which are selectively presented on the surface of cancer cells. By identifying T-cell receptors (TCRs) that induce potent anti-tumor responses against Dark Antigen targets, Enara Bio is creating a pipeline of targeted immunotherapies designed to improve treatment outcomes for broad patient populations. These Dark Antigens are homogenously expressed within tumors and shared across patients, offering a broader therapeutic potential than conventional tumor-associated antigens.
Target Audience
The primary target audience includes pharmaceutical companies seeking novel cancer-specific targets for immunotherapy development and researchers focused on advancing cancer immunology and T-cell biology.
Features
- EDAPT (Enara Dark Antigen Platform Technology) for Dark Antigen discovery and validation
- Proprietary bioinformatic databases to mine the genomic dark matter for novel cancer antigens
- Cutting-edge mass spectrometry-based immunopeptidomics to identify Dark Antigens on the tumor cell surface
- In situ hybridization to validate tumor cell specificity and homogeneity within patient samples
- TCR discovery platform to characterize the immune response elicited against Dark Antigens
- Screening of peripheral CD8+ T cells and tumor-infiltrating lymphocytes (TILs) to discover cognate TCRs
- Technologies to functionally screen T-cell libraries against cancer cells for TCRs with pan-cancer activity